Jump to content
RemedySpot.com

4 New HCV Abstracts

Rate this topic


Recommended Posts

Posted

J Hepatol. 2010 Dec 8. [Epub ahead of print]

Association Of Caffeine Intake and Histological Features of Chronic Hepatitis C.

Costentin CE, Roudot-Thoraval F, Zafrani ES, Medkour F, Pawlotsky JM, Mallat A,

Hézode C.

AP-HP, Service d'Hépatologie et de Gastroentérologie, Groupe Hospitalier Henri

Mondor-Albert Chenevier, Créteil, 94000 France.

Abstract

Rational The severity of chronic hepatitis C (CHC) is modulated by host and

environmental factors. Several reports suggest that caffeine intake exerts

hepatoprotective effects in patients with chronic liver disease. The aim of this

study was to evaluate the impact of caffeine consumption on activity grade and

fibrosis stage in patients with CHC. Methods 238 treatment-naı¨ve patients

with histologically-proven CHC were included. Demographic, epidemiological,

environmental, virological and metabolic features were collected, including

daily consumptions of alcohol, cannabis, tobacco and caffeine during the six

month preceding liver biopsy. Daily caffeine consumption was estimated as the

sum of mean intakes of caffeinated coffee, tea and caffeine-containing sodas.

Histological activity grade and fibrosis stage were scored according to Metavir.

Patients (154 men, 84 women, mean age: 45±11 years) were categorized according

to caffeine consumption quartiles: group 1 (<225 mg/day, n=59), group 2 (225-407

mg/day, n=57), group 3 (408-678 mg/day, n=62) and group 4 (>678 mg/day, n=60).

Results There was a significant inverse relationship between activity grade and

daily caffeine consumption: Activity grade >A2 was present in 78%, 61%, 52% and

48% of patients in group 1, 2, 3 and 4, respectively (p<0.001). By multivariate

analysis, daily caffeine consumption greater than 408 mg/day was associated with

a lesser risk of activity grade >A2 (OR=0.32 (0.12-0.85)). Caffeine intake

showed no relation with the fibrosis stage. Conclusions Caffeine consumption

greater than 408 mg/day (3 cups or more) is associated with reduced histological

activity in patients with CHC. These findings support potential hepatoprotective

properties of caffeine in chronic liver diseases.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145804 [PubMed - as supplied by publisher]

J Hepatol. 2010 Dec 8. [Epub ahead of print]

Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated

with chronic hepatitis C and poor response to interferon-alfa based therapy.

Lange CM, Bojunga J, Ramos- E, Wagner MV, Hassler A, Vermehren J, Herrmann

E, Badenhoop K, Zeuzem S, Sarrazin C.

Klinikum der J. W. Goethe-Universität furt am Main, Medizinische Klinik 1,

Theodor-Stern-Kai 7, 60590 furt am Main, Germany.

Abstract

AIMS: Vitamin D is an important immune modulator and preliminary data indicated

an association between vitamin D deficiency and sustained virologic response

(SVR) rates in hepatitis C virus (HCV) genotype 1 patients. We therefore

performed a comprehensive analysis on the impact of vitamin D serum levels and

of genetic polymorphisms with functional relevance within the vitamin D cascade

on chronic hepatitis C and its treatment

METHODS: Vitamin D serum levels, genetic polymorphisms within the vitamin D

receptor and 1α-hydroxylase were determined in a cohort of 468 HCV genotype 1,

2 and 3 infected patients who were treated with interferon-alfa based regimens

RESULTS: Chronic hepatitis C was associated with a high incidence of severe

vitamin D deficiency compared to controls (25(OH)D(3)<10 ng/ml in 25% versus

12%, p<0.00001). 25(OH)D(3) deficiency correlated with SVR in HCV genotype 2 and

3 patients (50% and 81% SVR for patients with and without severe vitamin D

deficiency, respectively, p<0.0001). In addition, the CYPB27-1260 promoter

polymorphism rs10877012 had substantial impact on 1-25-dihydroxyvitamin D serum

levels (72, 61, and 60 pmol/ml for rs10877012 AA, AC, and CC, respectively,

p=0.04) and on SVR rates in HCV genotype 1, 2 and 3 infected patients (77% and

65% versus 42% for rs10877012 AA, AC, and CC, respectively, p=0.02)

CONCLUSIONS: Chronic hepatitis C virus infection is associated with vitamin D

deficiency. Reduced 25-hydroxyvitamin D levels and CYPB27-1260 promotor

polymorphism leading to reduced 1,25-dihydroxyvitamin D levels are associated

with failure to achieve SVR in HCV genotype 1, 2, 3 infected patients.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145801 [PubMed - as supplied by publisher]

J Virol. 2010 Dec 15. [Epub ahead of print]

Production of hepatitis C virus lacking the envelope-encoding genes for

single-cycle infection by providing homologous envelope proteins or vesicular

stomatitis virus glycoproteins in trans.

Li R, Qin Y, He Y, Tao W, Zhang N, Tsai C, Zhou P, Zhong J.

Unit of Viral Hepatitis, Unit of Antiviral immunity and genetic therapy, Key

Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai,

Shanghai Institutes for Biological Sciences, Chinese Academy of Science,

Shanghai, 200025, China.

Abstract

Hepatitis C virus (HCV) infection is a major worldwide health problem. The

envelope glycoproteins are the major components of viral particles. Here we

developed a trans-complementation system that allows the production of

infectious HCV particles containing the envelope protein-encoding regions

deleted genome (HCVΔE). The lack of envelope proteins could be efficiently

complemented by the expression of homologous envelope proteins in trans. HCVΔE

production could be enhanced significantly by previously described adaptive

mutations in NS3 and NS5A. Moreover, HCVΔE could be propagated and passaged in

the packaging cells stably expressing HCV envelope proteins while only resulted

in single-round infection in wild-type cells. Interestingly, we found that

vesicular stomatitis virus (VSV) glycoproteins could efficiently rescue the

production of HCV lacking endogenous envelope proteins, which no longer required

apolipoprotein E for virus production. The VSV glycoprotein-mediated viral entry

could allow for the bypass of natural HCV entry process and the delivery of HCV

replicon RNA into HCV receptor deficient cells. Our development provided a new

tool to produce single-cycle infectious HCV particles which should be useful for

studying individual steps of HCV life cycle, and may also provide a new strategy

for HCV vaccine development.

PMID: 21159872 [PubMed - as supplied by publisher]

J Viral Hepat. 2010 Dec 8. doi: 10.1111/j.1365-2893.2010.01408.x. [Epub ahead of

print]

Persistent pro-inflammatory cytokines following the initiation of pegylated IFN

therapy in hepatitis C infection is associated with treatment-induced

depression.

Krueger C, Hawkins K, Wong S, Enns MW, Minuk G, Rempel JD.

Section of Hepatology, Department of Internal Medicine, University of Manitoba,

Winnipeg, MB, Canada Department of Immunology, University of Manitoba, Winnipeg,

MB, Canada Department of Psychiatry, University of Manitoba, Winnipeg, MB,

Canada.

Abstract

Summary.  Pegylated interferon (IFN), the basis for chronic hepatitis C virus

(HCV) treatment, causes depression in 30-40% of patients. The potential for

cytokine mRNA patterns from baseline into early treatment to associate with the

onset of treatment-induced depression (TID) was examined. Depression was

measured by the Beck Depression Inventory at baseline and weeks 2, 4, 8 and 12

of treatment (n = 38). At baseline and weeks 2 and 4, peripheral blood

mononuclear cell (PMBC, n = 28), isolated ex vivo, were examined for tumour

neurosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 mRNA expression.

In patients that developed treatment-induced depression, pro-inflammatory

TNF-alpha mRNA levels from baseline into week 4 of therapy remained constant

(1.1-fold increase); whereas IL-1beta transcripts decreased 3.5 fold. However,

corresponding TNF-alpha (3-fold, P < 0.05) and IL-1beta (7.5-fold)

transcript expression diminished to a greater extent in the absence of TID.

Changes in TNF-alpha mRNA values correlated to the average change in BDI scores

over the 12 weeks (r = 0.56, P < 0.05). Concomitantly,

anti-inflammatory IL-10 transcript levels decreased in (TID), relative to

increased expression in the absence of TID (P < 0.05). The potential

influence of IL-10 was observed upon calculation of individual pro- verses

anti-inflammatory mRNA ratios. Stable in the presence of depression,

TNF-alpha/IL-10 and IL-1beta/IL-10 mRNA ratios declined significantly over time

in its absence (P < 0.05). This study suggests that in chronic HCV

infection, upon pegylated IFN administration persistent pro-inflammatory

cytokine MRNA expression associates with TID. In contrast, therapeutic

activation of mechanisms that decrease pro-inflammatory immunity may protect

against depression during therapy.

© 2010 Blackwell Publishing Ltd.

PMID: 21143344 [PubMed - as supplied by publisher]

Posted

J Hepatol. 2010 Dec 8. [Epub ahead of print]

Association Of Caffeine Intake and Histological Features of Chronic Hepatitis C.

Costentin CE, Roudot-Thoraval F, Zafrani ES, Medkour F, Pawlotsky JM, Mallat A,

Hézode C.

AP-HP, Service d'Hépatologie et de Gastroentérologie, Groupe Hospitalier Henri

Mondor-Albert Chenevier, Créteil, 94000 France.

Abstract

Rational The severity of chronic hepatitis C (CHC) is modulated by host and

environmental factors. Several reports suggest that caffeine intake exerts

hepatoprotective effects in patients with chronic liver disease. The aim of this

study was to evaluate the impact of caffeine consumption on activity grade and

fibrosis stage in patients with CHC. Methods 238 treatment-naı¨ve patients

with histologically-proven CHC were included. Demographic, epidemiological,

environmental, virological and metabolic features were collected, including

daily consumptions of alcohol, cannabis, tobacco and caffeine during the six

month preceding liver biopsy. Daily caffeine consumption was estimated as the

sum of mean intakes of caffeinated coffee, tea and caffeine-containing sodas.

Histological activity grade and fibrosis stage were scored according to Metavir.

Patients (154 men, 84 women, mean age: 45±11 years) were categorized according

to caffeine consumption quartiles: group 1 (<225 mg/day, n=59), group 2 (225-407

mg/day, n=57), group 3 (408-678 mg/day, n=62) and group 4 (>678 mg/day, n=60).

Results There was a significant inverse relationship between activity grade and

daily caffeine consumption: Activity grade >A2 was present in 78%, 61%, 52% and

48% of patients in group 1, 2, 3 and 4, respectively (p<0.001). By multivariate

analysis, daily caffeine consumption greater than 408 mg/day was associated with

a lesser risk of activity grade >A2 (OR=0.32 (0.12-0.85)). Caffeine intake

showed no relation with the fibrosis stage. Conclusions Caffeine consumption

greater than 408 mg/day (3 cups or more) is associated with reduced histological

activity in patients with CHC. These findings support potential hepatoprotective

properties of caffeine in chronic liver diseases.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145804 [PubMed - as supplied by publisher]

J Hepatol. 2010 Dec 8. [Epub ahead of print]

Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated

with chronic hepatitis C and poor response to interferon-alfa based therapy.

Lange CM, Bojunga J, Ramos- E, Wagner MV, Hassler A, Vermehren J, Herrmann

E, Badenhoop K, Zeuzem S, Sarrazin C.

Klinikum der J. W. Goethe-Universität furt am Main, Medizinische Klinik 1,

Theodor-Stern-Kai 7, 60590 furt am Main, Germany.

Abstract

AIMS: Vitamin D is an important immune modulator and preliminary data indicated

an association between vitamin D deficiency and sustained virologic response

(SVR) rates in hepatitis C virus (HCV) genotype 1 patients. We therefore

performed a comprehensive analysis on the impact of vitamin D serum levels and

of genetic polymorphisms with functional relevance within the vitamin D cascade

on chronic hepatitis C and its treatment

METHODS: Vitamin D serum levels, genetic polymorphisms within the vitamin D

receptor and 1α-hydroxylase were determined in a cohort of 468 HCV genotype 1,

2 and 3 infected patients who were treated with interferon-alfa based regimens

RESULTS: Chronic hepatitis C was associated with a high incidence of severe

vitamin D deficiency compared to controls (25(OH)D(3)<10 ng/ml in 25% versus

12%, p<0.00001). 25(OH)D(3) deficiency correlated with SVR in HCV genotype 2 and

3 patients (50% and 81% SVR for patients with and without severe vitamin D

deficiency, respectively, p<0.0001). In addition, the CYPB27-1260 promoter

polymorphism rs10877012 had substantial impact on 1-25-dihydroxyvitamin D serum

levels (72, 61, and 60 pmol/ml for rs10877012 AA, AC, and CC, respectively,

p=0.04) and on SVR rates in HCV genotype 1, 2 and 3 infected patients (77% and

65% versus 42% for rs10877012 AA, AC, and CC, respectively, p=0.02)

CONCLUSIONS: Chronic hepatitis C virus infection is associated with vitamin D

deficiency. Reduced 25-hydroxyvitamin D levels and CYPB27-1260 promotor

polymorphism leading to reduced 1,25-dihydroxyvitamin D levels are associated

with failure to achieve SVR in HCV genotype 1, 2, 3 infected patients.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145801 [PubMed - as supplied by publisher]

J Virol. 2010 Dec 15. [Epub ahead of print]

Production of hepatitis C virus lacking the envelope-encoding genes for

single-cycle infection by providing homologous envelope proteins or vesicular

stomatitis virus glycoproteins in trans.

Li R, Qin Y, He Y, Tao W, Zhang N, Tsai C, Zhou P, Zhong J.

Unit of Viral Hepatitis, Unit of Antiviral immunity and genetic therapy, Key

Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai,

Shanghai Institutes for Biological Sciences, Chinese Academy of Science,

Shanghai, 200025, China.

Abstract

Hepatitis C virus (HCV) infection is a major worldwide health problem. The

envelope glycoproteins are the major components of viral particles. Here we

developed a trans-complementation system that allows the production of

infectious HCV particles containing the envelope protein-encoding regions

deleted genome (HCVΔE). The lack of envelope proteins could be efficiently

complemented by the expression of homologous envelope proteins in trans. HCVΔE

production could be enhanced significantly by previously described adaptive

mutations in NS3 and NS5A. Moreover, HCVΔE could be propagated and passaged in

the packaging cells stably expressing HCV envelope proteins while only resulted

in single-round infection in wild-type cells. Interestingly, we found that

vesicular stomatitis virus (VSV) glycoproteins could efficiently rescue the

production of HCV lacking endogenous envelope proteins, which no longer required

apolipoprotein E for virus production. The VSV glycoprotein-mediated viral entry

could allow for the bypass of natural HCV entry process and the delivery of HCV

replicon RNA into HCV receptor deficient cells. Our development provided a new

tool to produce single-cycle infectious HCV particles which should be useful for

studying individual steps of HCV life cycle, and may also provide a new strategy

for HCV vaccine development.

PMID: 21159872 [PubMed - as supplied by publisher]

J Viral Hepat. 2010 Dec 8. doi: 10.1111/j.1365-2893.2010.01408.x. [Epub ahead of

print]

Persistent pro-inflammatory cytokines following the initiation of pegylated IFN

therapy in hepatitis C infection is associated with treatment-induced

depression.

Krueger C, Hawkins K, Wong S, Enns MW, Minuk G, Rempel JD.

Section of Hepatology, Department of Internal Medicine, University of Manitoba,

Winnipeg, MB, Canada Department of Immunology, University of Manitoba, Winnipeg,

MB, Canada Department of Psychiatry, University of Manitoba, Winnipeg, MB,

Canada.

Abstract

Summary.  Pegylated interferon (IFN), the basis for chronic hepatitis C virus

(HCV) treatment, causes depression in 30-40% of patients. The potential for

cytokine mRNA patterns from baseline into early treatment to associate with the

onset of treatment-induced depression (TID) was examined. Depression was

measured by the Beck Depression Inventory at baseline and weeks 2, 4, 8 and 12

of treatment (n = 38). At baseline and weeks 2 and 4, peripheral blood

mononuclear cell (PMBC, n = 28), isolated ex vivo, were examined for tumour

neurosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 mRNA expression.

In patients that developed treatment-induced depression, pro-inflammatory

TNF-alpha mRNA levels from baseline into week 4 of therapy remained constant

(1.1-fold increase); whereas IL-1beta transcripts decreased 3.5 fold. However,

corresponding TNF-alpha (3-fold, P < 0.05) and IL-1beta (7.5-fold)

transcript expression diminished to a greater extent in the absence of TID.

Changes in TNF-alpha mRNA values correlated to the average change in BDI scores

over the 12 weeks (r = 0.56, P < 0.05). Concomitantly,

anti-inflammatory IL-10 transcript levels decreased in (TID), relative to

increased expression in the absence of TID (P < 0.05). The potential

influence of IL-10 was observed upon calculation of individual pro- verses

anti-inflammatory mRNA ratios. Stable in the presence of depression,

TNF-alpha/IL-10 and IL-1beta/IL-10 mRNA ratios declined significantly over time

in its absence (P < 0.05). This study suggests that in chronic HCV

infection, upon pegylated IFN administration persistent pro-inflammatory

cytokine MRNA expression associates with TID. In contrast, therapeutic

activation of mechanisms that decrease pro-inflammatory immunity may protect

against depression during therapy.

© 2010 Blackwell Publishing Ltd.

PMID: 21143344 [PubMed - as supplied by publisher]

Posted

J Hepatol. 2010 Dec 8. [Epub ahead of print]

Association Of Caffeine Intake and Histological Features of Chronic Hepatitis C.

Costentin CE, Roudot-Thoraval F, Zafrani ES, Medkour F, Pawlotsky JM, Mallat A,

Hézode C.

AP-HP, Service d'Hépatologie et de Gastroentérologie, Groupe Hospitalier Henri

Mondor-Albert Chenevier, Créteil, 94000 France.

Abstract

Rational The severity of chronic hepatitis C (CHC) is modulated by host and

environmental factors. Several reports suggest that caffeine intake exerts

hepatoprotective effects in patients with chronic liver disease. The aim of this

study was to evaluate the impact of caffeine consumption on activity grade and

fibrosis stage in patients with CHC. Methods 238 treatment-naı¨ve patients

with histologically-proven CHC were included. Demographic, epidemiological,

environmental, virological and metabolic features were collected, including

daily consumptions of alcohol, cannabis, tobacco and caffeine during the six

month preceding liver biopsy. Daily caffeine consumption was estimated as the

sum of mean intakes of caffeinated coffee, tea and caffeine-containing sodas.

Histological activity grade and fibrosis stage were scored according to Metavir.

Patients (154 men, 84 women, mean age: 45±11 years) were categorized according

to caffeine consumption quartiles: group 1 (<225 mg/day, n=59), group 2 (225-407

mg/day, n=57), group 3 (408-678 mg/day, n=62) and group 4 (>678 mg/day, n=60).

Results There was a significant inverse relationship between activity grade and

daily caffeine consumption: Activity grade >A2 was present in 78%, 61%, 52% and

48% of patients in group 1, 2, 3 and 4, respectively (p<0.001). By multivariate

analysis, daily caffeine consumption greater than 408 mg/day was associated with

a lesser risk of activity grade >A2 (OR=0.32 (0.12-0.85)). Caffeine intake

showed no relation with the fibrosis stage. Conclusions Caffeine consumption

greater than 408 mg/day (3 cups or more) is associated with reduced histological

activity in patients with CHC. These findings support potential hepatoprotective

properties of caffeine in chronic liver diseases.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145804 [PubMed - as supplied by publisher]

J Hepatol. 2010 Dec 8. [Epub ahead of print]

Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated

with chronic hepatitis C and poor response to interferon-alfa based therapy.

Lange CM, Bojunga J, Ramos- E, Wagner MV, Hassler A, Vermehren J, Herrmann

E, Badenhoop K, Zeuzem S, Sarrazin C.

Klinikum der J. W. Goethe-Universität furt am Main, Medizinische Klinik 1,

Theodor-Stern-Kai 7, 60590 furt am Main, Germany.

Abstract

AIMS: Vitamin D is an important immune modulator and preliminary data indicated

an association between vitamin D deficiency and sustained virologic response

(SVR) rates in hepatitis C virus (HCV) genotype 1 patients. We therefore

performed a comprehensive analysis on the impact of vitamin D serum levels and

of genetic polymorphisms with functional relevance within the vitamin D cascade

on chronic hepatitis C and its treatment

METHODS: Vitamin D serum levels, genetic polymorphisms within the vitamin D

receptor and 1α-hydroxylase were determined in a cohort of 468 HCV genotype 1,

2 and 3 infected patients who were treated with interferon-alfa based regimens

RESULTS: Chronic hepatitis C was associated with a high incidence of severe

vitamin D deficiency compared to controls (25(OH)D(3)<10 ng/ml in 25% versus

12%, p<0.00001). 25(OH)D(3) deficiency correlated with SVR in HCV genotype 2 and

3 patients (50% and 81% SVR for patients with and without severe vitamin D

deficiency, respectively, p<0.0001). In addition, the CYPB27-1260 promoter

polymorphism rs10877012 had substantial impact on 1-25-dihydroxyvitamin D serum

levels (72, 61, and 60 pmol/ml for rs10877012 AA, AC, and CC, respectively,

p=0.04) and on SVR rates in HCV genotype 1, 2 and 3 infected patients (77% and

65% versus 42% for rs10877012 AA, AC, and CC, respectively, p=0.02)

CONCLUSIONS: Chronic hepatitis C virus infection is associated with vitamin D

deficiency. Reduced 25-hydroxyvitamin D levels and CYPB27-1260 promotor

polymorphism leading to reduced 1,25-dihydroxyvitamin D levels are associated

with failure to achieve SVR in HCV genotype 1, 2, 3 infected patients.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145801 [PubMed - as supplied by publisher]

J Virol. 2010 Dec 15. [Epub ahead of print]

Production of hepatitis C virus lacking the envelope-encoding genes for

single-cycle infection by providing homologous envelope proteins or vesicular

stomatitis virus glycoproteins in trans.

Li R, Qin Y, He Y, Tao W, Zhang N, Tsai C, Zhou P, Zhong J.

Unit of Viral Hepatitis, Unit of Antiviral immunity and genetic therapy, Key

Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai,

Shanghai Institutes for Biological Sciences, Chinese Academy of Science,

Shanghai, 200025, China.

Abstract

Hepatitis C virus (HCV) infection is a major worldwide health problem. The

envelope glycoproteins are the major components of viral particles. Here we

developed a trans-complementation system that allows the production of

infectious HCV particles containing the envelope protein-encoding regions

deleted genome (HCVΔE). The lack of envelope proteins could be efficiently

complemented by the expression of homologous envelope proteins in trans. HCVΔE

production could be enhanced significantly by previously described adaptive

mutations in NS3 and NS5A. Moreover, HCVΔE could be propagated and passaged in

the packaging cells stably expressing HCV envelope proteins while only resulted

in single-round infection in wild-type cells. Interestingly, we found that

vesicular stomatitis virus (VSV) glycoproteins could efficiently rescue the

production of HCV lacking endogenous envelope proteins, which no longer required

apolipoprotein E for virus production. The VSV glycoprotein-mediated viral entry

could allow for the bypass of natural HCV entry process and the delivery of HCV

replicon RNA into HCV receptor deficient cells. Our development provided a new

tool to produce single-cycle infectious HCV particles which should be useful for

studying individual steps of HCV life cycle, and may also provide a new strategy

for HCV vaccine development.

PMID: 21159872 [PubMed - as supplied by publisher]

J Viral Hepat. 2010 Dec 8. doi: 10.1111/j.1365-2893.2010.01408.x. [Epub ahead of

print]

Persistent pro-inflammatory cytokines following the initiation of pegylated IFN

therapy in hepatitis C infection is associated with treatment-induced

depression.

Krueger C, Hawkins K, Wong S, Enns MW, Minuk G, Rempel JD.

Section of Hepatology, Department of Internal Medicine, University of Manitoba,

Winnipeg, MB, Canada Department of Immunology, University of Manitoba, Winnipeg,

MB, Canada Department of Psychiatry, University of Manitoba, Winnipeg, MB,

Canada.

Abstract

Summary.  Pegylated interferon (IFN), the basis for chronic hepatitis C virus

(HCV) treatment, causes depression in 30-40% of patients. The potential for

cytokine mRNA patterns from baseline into early treatment to associate with the

onset of treatment-induced depression (TID) was examined. Depression was

measured by the Beck Depression Inventory at baseline and weeks 2, 4, 8 and 12

of treatment (n = 38). At baseline and weeks 2 and 4, peripheral blood

mononuclear cell (PMBC, n = 28), isolated ex vivo, were examined for tumour

neurosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 mRNA expression.

In patients that developed treatment-induced depression, pro-inflammatory

TNF-alpha mRNA levels from baseline into week 4 of therapy remained constant

(1.1-fold increase); whereas IL-1beta transcripts decreased 3.5 fold. However,

corresponding TNF-alpha (3-fold, P < 0.05) and IL-1beta (7.5-fold)

transcript expression diminished to a greater extent in the absence of TID.

Changes in TNF-alpha mRNA values correlated to the average change in BDI scores

over the 12 weeks (r = 0.56, P < 0.05). Concomitantly,

anti-inflammatory IL-10 transcript levels decreased in (TID), relative to

increased expression in the absence of TID (P < 0.05). The potential

influence of IL-10 was observed upon calculation of individual pro- verses

anti-inflammatory mRNA ratios. Stable in the presence of depression,

TNF-alpha/IL-10 and IL-1beta/IL-10 mRNA ratios declined significantly over time

in its absence (P < 0.05). This study suggests that in chronic HCV

infection, upon pegylated IFN administration persistent pro-inflammatory

cytokine MRNA expression associates with TID. In contrast, therapeutic

activation of mechanisms that decrease pro-inflammatory immunity may protect

against depression during therapy.

© 2010 Blackwell Publishing Ltd.

PMID: 21143344 [PubMed - as supplied by publisher]

Posted

J Hepatol. 2010 Dec 8. [Epub ahead of print]

Association Of Caffeine Intake and Histological Features of Chronic Hepatitis C.

Costentin CE, Roudot-Thoraval F, Zafrani ES, Medkour F, Pawlotsky JM, Mallat A,

Hézode C.

AP-HP, Service d'Hépatologie et de Gastroentérologie, Groupe Hospitalier Henri

Mondor-Albert Chenevier, Créteil, 94000 France.

Abstract

Rational The severity of chronic hepatitis C (CHC) is modulated by host and

environmental factors. Several reports suggest that caffeine intake exerts

hepatoprotective effects in patients with chronic liver disease. The aim of this

study was to evaluate the impact of caffeine consumption on activity grade and

fibrosis stage in patients with CHC. Methods 238 treatment-naı¨ve patients

with histologically-proven CHC were included. Demographic, epidemiological,

environmental, virological and metabolic features were collected, including

daily consumptions of alcohol, cannabis, tobacco and caffeine during the six

month preceding liver biopsy. Daily caffeine consumption was estimated as the

sum of mean intakes of caffeinated coffee, tea and caffeine-containing sodas.

Histological activity grade and fibrosis stage were scored according to Metavir.

Patients (154 men, 84 women, mean age: 45±11 years) were categorized according

to caffeine consumption quartiles: group 1 (<225 mg/day, n=59), group 2 (225-407

mg/day, n=57), group 3 (408-678 mg/day, n=62) and group 4 (>678 mg/day, n=60).

Results There was a significant inverse relationship between activity grade and

daily caffeine consumption: Activity grade >A2 was present in 78%, 61%, 52% and

48% of patients in group 1, 2, 3 and 4, respectively (p<0.001). By multivariate

analysis, daily caffeine consumption greater than 408 mg/day was associated with

a lesser risk of activity grade >A2 (OR=0.32 (0.12-0.85)). Caffeine intake

showed no relation with the fibrosis stage. Conclusions Caffeine consumption

greater than 408 mg/day (3 cups or more) is associated with reduced histological

activity in patients with CHC. These findings support potential hepatoprotective

properties of caffeine in chronic liver diseases.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145804 [PubMed - as supplied by publisher]

J Hepatol. 2010 Dec 8. [Epub ahead of print]

Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated

with chronic hepatitis C and poor response to interferon-alfa based therapy.

Lange CM, Bojunga J, Ramos- E, Wagner MV, Hassler A, Vermehren J, Herrmann

E, Badenhoop K, Zeuzem S, Sarrazin C.

Klinikum der J. W. Goethe-Universität furt am Main, Medizinische Klinik 1,

Theodor-Stern-Kai 7, 60590 furt am Main, Germany.

Abstract

AIMS: Vitamin D is an important immune modulator and preliminary data indicated

an association between vitamin D deficiency and sustained virologic response

(SVR) rates in hepatitis C virus (HCV) genotype 1 patients. We therefore

performed a comprehensive analysis on the impact of vitamin D serum levels and

of genetic polymorphisms with functional relevance within the vitamin D cascade

on chronic hepatitis C and its treatment

METHODS: Vitamin D serum levels, genetic polymorphisms within the vitamin D

receptor and 1α-hydroxylase were determined in a cohort of 468 HCV genotype 1,

2 and 3 infected patients who were treated with interferon-alfa based regimens

RESULTS: Chronic hepatitis C was associated with a high incidence of severe

vitamin D deficiency compared to controls (25(OH)D(3)<10 ng/ml in 25% versus

12%, p<0.00001). 25(OH)D(3) deficiency correlated with SVR in HCV genotype 2 and

3 patients (50% and 81% SVR for patients with and without severe vitamin D

deficiency, respectively, p<0.0001). In addition, the CYPB27-1260 promoter

polymorphism rs10877012 had substantial impact on 1-25-dihydroxyvitamin D serum

levels (72, 61, and 60 pmol/ml for rs10877012 AA, AC, and CC, respectively,

p=0.04) and on SVR rates in HCV genotype 1, 2 and 3 infected patients (77% and

65% versus 42% for rs10877012 AA, AC, and CC, respectively, p=0.02)

CONCLUSIONS: Chronic hepatitis C virus infection is associated with vitamin D

deficiency. Reduced 25-hydroxyvitamin D levels and CYPB27-1260 promotor

polymorphism leading to reduced 1,25-dihydroxyvitamin D levels are associated

with failure to achieve SVR in HCV genotype 1, 2, 3 infected patients.

Copyright © 2010. Published by Elsevier B.V.

PMID: 21145801 [PubMed - as supplied by publisher]

J Virol. 2010 Dec 15. [Epub ahead of print]

Production of hepatitis C virus lacking the envelope-encoding genes for

single-cycle infection by providing homologous envelope proteins or vesicular

stomatitis virus glycoproteins in trans.

Li R, Qin Y, He Y, Tao W, Zhang N, Tsai C, Zhou P, Zhong J.

Unit of Viral Hepatitis, Unit of Antiviral immunity and genetic therapy, Key

Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai,

Shanghai Institutes for Biological Sciences, Chinese Academy of Science,

Shanghai, 200025, China.

Abstract

Hepatitis C virus (HCV) infection is a major worldwide health problem. The

envelope glycoproteins are the major components of viral particles. Here we

developed a trans-complementation system that allows the production of

infectious HCV particles containing the envelope protein-encoding regions

deleted genome (HCVΔE). The lack of envelope proteins could be efficiently

complemented by the expression of homologous envelope proteins in trans. HCVΔE

production could be enhanced significantly by previously described adaptive

mutations in NS3 and NS5A. Moreover, HCVΔE could be propagated and passaged in

the packaging cells stably expressing HCV envelope proteins while only resulted

in single-round infection in wild-type cells. Interestingly, we found that

vesicular stomatitis virus (VSV) glycoproteins could efficiently rescue the

production of HCV lacking endogenous envelope proteins, which no longer required

apolipoprotein E for virus production. The VSV glycoprotein-mediated viral entry

could allow for the bypass of natural HCV entry process and the delivery of HCV

replicon RNA into HCV receptor deficient cells. Our development provided a new

tool to produce single-cycle infectious HCV particles which should be useful for

studying individual steps of HCV life cycle, and may also provide a new strategy

for HCV vaccine development.

PMID: 21159872 [PubMed - as supplied by publisher]

J Viral Hepat. 2010 Dec 8. doi: 10.1111/j.1365-2893.2010.01408.x. [Epub ahead of

print]

Persistent pro-inflammatory cytokines following the initiation of pegylated IFN

therapy in hepatitis C infection is associated with treatment-induced

depression.

Krueger C, Hawkins K, Wong S, Enns MW, Minuk G, Rempel JD.

Section of Hepatology, Department of Internal Medicine, University of Manitoba,

Winnipeg, MB, Canada Department of Immunology, University of Manitoba, Winnipeg,

MB, Canada Department of Psychiatry, University of Manitoba, Winnipeg, MB,

Canada.

Abstract

Summary.  Pegylated interferon (IFN), the basis for chronic hepatitis C virus

(HCV) treatment, causes depression in 30-40% of patients. The potential for

cytokine mRNA patterns from baseline into early treatment to associate with the

onset of treatment-induced depression (TID) was examined. Depression was

measured by the Beck Depression Inventory at baseline and weeks 2, 4, 8 and 12

of treatment (n = 38). At baseline and weeks 2 and 4, peripheral blood

mononuclear cell (PMBC, n = 28), isolated ex vivo, were examined for tumour

neurosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 mRNA expression.

In patients that developed treatment-induced depression, pro-inflammatory

TNF-alpha mRNA levels from baseline into week 4 of therapy remained constant

(1.1-fold increase); whereas IL-1beta transcripts decreased 3.5 fold. However,

corresponding TNF-alpha (3-fold, P < 0.05) and IL-1beta (7.5-fold)

transcript expression diminished to a greater extent in the absence of TID.

Changes in TNF-alpha mRNA values correlated to the average change in BDI scores

over the 12 weeks (r = 0.56, P < 0.05). Concomitantly,

anti-inflammatory IL-10 transcript levels decreased in (TID), relative to

increased expression in the absence of TID (P < 0.05). The potential

influence of IL-10 was observed upon calculation of individual pro- verses

anti-inflammatory mRNA ratios. Stable in the presence of depression,

TNF-alpha/IL-10 and IL-1beta/IL-10 mRNA ratios declined significantly over time

in its absence (P < 0.05). This study suggests that in chronic HCV

infection, upon pegylated IFN administration persistent pro-inflammatory

cytokine MRNA expression associates with TID. In contrast, therapeutic

activation of mechanisms that decrease pro-inflammatory immunity may protect

against depression during therapy.

© 2010 Blackwell Publishing Ltd.

PMID: 21143344 [PubMed - as supplied by publisher]

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...